Aptose Biosciences Inc (APTO)

2.650
-0.070(-2.57%)
After Hours
2.615
-0.035(-1.321%)
- Real-time Data
  • Volume:
    2,651,082
  • Bid/Ask:
    2.570/2.740
  • Day's Range:
    2.550 - 2.750

APTO Overview

Prev. Close
2.72
Day's Range
2.55-2.75
Revenue
-
Open
2.75
52 wk Range
2.55-7.27
EPS
-0.71
Volume
2,651,082
Market Cap
235.32M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,262,821
P/E Ratio
-
Beta
1.73
1-Year Change
-48.44%
Shares Outstanding
88,943,243
Next Earnings Date
02 Aug 2021
What is your sentiment on Aptose Biosciences Inc?
or
Market is currently closed. Voting is open during market hours.

Aptose Biosciences Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong SellStrong SellStrong Sell
SummaryStrong BuyBuyStrong SellStrong SellStrong Sell

Aptose Biosciences Inc Company Profile

Aptose Biosciences Inc Company Profile

Employees
0
Market
Canada

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806 and CG-806, which are in Phase 1a/b clinical trial for the treatment of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin’s lymphomas, as well as relapsed/refractory acute myeloid leukemia. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Read More
  • 2021.03.04. Smarter Analyst $4. Tgt $14.0. Consensus $11.20
    0
    • bought $3.97. Sold $6.66. Wait for it to drop further
      0
      • 2021.03.24.Sold @ $6.66. reached $7.20 earlier 🙃
        0
        • bought $3.97
          0
      • 2021.03.04. Smarter Analyst $4. Tgt $14.0. Consensus $11.20
        0
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.